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Abstract
Background:  We conducted a study aiming to describe Human Papillomavirus (HPV) type
distribution in invasive cervical carcinoma in Uganda.
Methods: 191 archival cervical carcinoma samples diagnosed in the Department of Pathology,
Makerere University in Kampala between 1968 and 1992 were analysed using a sensitive PCR-
Reverse Hybridization Line Probe Assay.
Results: Out of the 186 cases of confirmed invasive cervical cancer in the study paraffin blocks,
114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 109 cases: HPV 16,
18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases (96.3%) and
as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% (84/105) of cases with
single infection.
Conclusion: The results of this study confirm the role of HPV 16 and 18 in cervical cancer
pathogenesis in the Ugandan population. The results suggest that the currently available HPV
vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in
Uganda.
Background
Clinical and epidemiological studies have clearly estab-
lished that infections by certain human papillomaviruses
(HPVs) types are causally linked to cervical cancer devel-
opment [1-5]. Among the high risk HPV types, HPV 16
and 18 are recognized as the main causes of invasive cer-
vical cancer and its precursor lesions [3]. These two viral
types were found in most cases of invasive cervical cancer
from 22 countries around the world [4]. HPV 16 tends to
predominate in squamous cell carcinomas whereas HPV
18 often predominate in adenocarcinomas [4,6-8]. Some
studies have also shown that there are geographical varia-
tions in HPV type distribution [1,4,9,10]. Finally, recent
data shows that HPV immunization offers the greatest
possibility for prevention of cervical cancer and has
become an important health priority to many govern-
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ments and health organizations worldwide. HPV vaccines
that are currently available include VLPs for HPV 16 and
18 [11,12] as well as HPV 11 and 6 [13]. However, geo-
graphical variations in HPV type distribution might influ-
ence the currently available HPV vaccine efficacy.
Compared to other continents (such as South America
and Asia), there is relatively little information about HPV
types in invasive cervical cancer in Africa. We conducted a
study aiming to characterize HPV type spectrum in the
archival specimens from cervical cancer cases from
Uganda population including cases diagnosed over 34
years.
Methods
191 samples from patients with histological diagnosis of
invasive cervical carcinoma from 1968 to 1992 were
obtained from the archives of the Department of Pathol-
ogy, Makerere University in Kampala, Uganda. These sam-
ples accounted for less than 5% of cervical carcinomas
diagnosed during the study period. Nine cases (4.7%)
were from the period of 1968 to 1969, 66 (34.6%) cases
from 1970–1979, 74 (38.7%) from 1980–1989 and 42
(22.0%) were from the period 1990–1992. Until the early
nineties, the Department of Pathology received most spec-
imens for histopathology services from all hospitals and
health facilities in the country.
Samples were received in formalin, which may not always
have been buffered. Tissue specimens were usually proc-
essed within 24 hours of their arrival to the hospital, but
for a fraction of samples transported from remote parts of
the country, longer times may have been required. Sam-
ples were selected randomly from the register of Pathol-
ogy Department starting in 1968; we oversampled of
adenocarcinomas (1:1) because of the special interest to
compare genotype distribution in the two major histolo-
gies of cervical cancer.
When at the testing laboratory, the paraffin embedded tis-
sue blocks were re-embedded in fresh paraffin wax and
four sections (sandwich method) were cut for testing
under strict conditions to avoid potential contamination.
The first and the last sections were stained with Haema-
toxylin and Eosin (H&E) to confirm diagnosis and to
ascertain the suitability of the tissue to continue for HPV
testing. The sections in-between were collected in a screw-
top Eppendorf tube for HPV testing. A tissue-free paraffin
block was cut after each study block to avoid any HPV
carry-over from block to block. A new blade was used for
each block and the microtome was cleaned with a vacuum
cleaner, Histoclear II and 70% alcohol. To further control
for possible sources of contamination, paraffin blocks
containing non HPV related lesions (appendicitis, lung
tumour, ovary, lymph node etc.) were included blindly in
the process at a ratio of 5%, and blank paraffin sections
were simultaneously tested.
Proteinase K (Sigma) digestion for 16 hours at 56°C tem-
perature was used to obtain a tissue lysate containing
DNA from the paraffin inner 5 μm sections. SPF10 PCR
was performed using 10 μl of a 1:10 dilution with water
of the tissue digest in a final reaction volume of 50 μl [14].
The amplified PCR products were tested using a probe
hybridization with a cocktail of conservative probes recog-
nizing at least 54 mucosal HPV genotypes in a microtitre
plate format for the detection of HPV DNA. Optical den-
sities (OD450) were read on a microtitre plate reader. HPV
DNA positive samples were subsequently analysed by
HPV SPF10-LIPA25 (version 1: produced at Labo Biomed-
ical Products, Rijswijk, The Netherlands) [14], a reverse
hybridization technique that detects 25 high-risk and low-
risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 74).
The sequence variation within the SPF10 primers allows
the recognition of these different HPV genotypes, except
for the types 68 and 73 as their interprimer regions are
identical and cannot be distinguished on this test. After
PCR, 10 μl of the amplimers was used to perform reverse
hybridization for HPV genotype identification. The posi-
tive hybridization on the strips is visualized as a purple
band by means of a precipitating colour substrate on the
probe site. Specimens that were HPV/DNA positive but
did not hybridize with any of the 25 probes were coded as
HPV type X (unknown type). Amplification of a fragment
of the human β-globin gene was performed in all HPV/
DNA negative samples to assess DNA quality. HPV type-
specific distributions were calculated among HPV positive
women. All SPF10-LIPA25 PCR detection and typing was
performed at the facilities of DDL Diagnostic Laboratories
(DDL, Voorburg, Netherlands) and at Institut Català
d'Oncologia (ICO, Barcelona). HPV detection was evalu-
ated by histology classification (adenocarcinoma vs. squa-
mous cell carcinoma), year of diagnosis and presence of
necrosis in the tissue.
Ethical approval for the reported study was obtained from
Ethical Committee at Makerere University, Kampala,
Uganda.
Results
Of the 191 paraffin blocks corresponding each one to a
cervical cancer cases, 186 harboured invasive cervical car-
cinoma cells and, according to protocol, were considered
suitable for HPV detection. Five were excluded due to
extended necroses seen on the histological slide. 146 were
diagnosed as squamous carcinomas, 35 were adenocarci-
nomas, 3 adenosquamous and two were undifferentiated
carcinomas. Out of these, 114 were HPV positive and in
72 HPV could not be detected. All the negative samplesBMC Infectious Diseases 2008, 8:85 http://www.biomedcentral.com/1471-2334/8/85
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tested negative for the presence of β-globin gene indicat-
ing a poor quality tissue. Table 1 shows the overall β-
globin gene and HPV positivity results according to histo-
logical types. There was no statistical differences between
histological type and overall HPV infection (Chi2 = 3.64,
p = 0.3). There was stability of genotype distribution of
HPV 16 and HPV 18 over time, taking into account histol-
ogy.
Specific HPV types were identifiable in 109 cases, while in
the remaining five cases no specific HPV types could be
identified (Type X). Ten specific HPV types: 16, 18, 31, 35,
39, 44, 45, 51, 52 and 70 were identified. These occurred
as single infections in 105 cases, double infections in
three cases and triple infections in one case. Analysis of
the HPV genotypes distribution among the HPV positive
cases showed that HPV 16 and 18 were the most frequent
types, followed in descending order by HPV 45, 31, 35,
51, 39 and 52. Table 2 shows the distribution of HPV
infections and histological types.
In single infections, type 16 occurred in 51 of the cases,
type 18 in 33 cases, type 45 in 11 cases, type 31 in four
cases, type 35 and 51 in two cases, types 39 and 52 each
in one case. The three double infections were found to be
combinations of types 16/45, 16/51 and 45/70 while the
triple infections included the HPV types16/44/52. When
the analysis was restricted to the histological types of cer-
vical carcinoma, HPV 16 was the most frequent in squa-
mous cell carcinomas (47.8% of cases) while in
adenocarcinomas, HPV 18 was the most prevalent type
(50%). Of the squamous cell carcinomas, 44 of the cases
Table 1: HPV/DNA detection by cervical cancer histological types
HPV negativea HPV positiveb Total
Squamous carcinoma 54 92 146
Adenocarcinoma 15 20 35
Adenosquamous 1 2 3
Undifferentiated carcinoma 2 0 2
Total 72 114 186
a HPV not detected. All these samples were human β-globin gene negative, and therefore inadequate for HPV determination
b All β-globin gene positive
Table 2: HPV type distribution according to histological types
HPV types Squamous carcinomas Adenocarcinomas Total
Infection with single HPV 110 (96,5%)
N (%) N (%) N (%)
HPV 16 44 (47.8) 7 (35.0) 51 (44.7)
HPV 18 21 (22.8) 10 (50.0) 33 (28.8)a
HPV 16 or 18 65 (70.6) 17 (85.0) 84 (73.7)a
HPV 31 4 (4.3) 0 4 (3.5)
HPV 35 2 (2.2) 0 2 (1.8)
HPV 39 1 (1.1) 0 1 (0.9)
HPV 45 10 (10.9) 1 (5.0) 11 (9.6)
HPV 51 1 (1.1) 1 (5.0) 2 (1.8)
HPV 52 1 (1.1) 0 1 (0.9)
Type X 4 (4.3) 1 (5) 5 (4.4)
Infection with multiple HPV 4 (3.5%)
HPV 16/45 1 (1.1) 0 1 (0.9)
HPV 16/51 1 (1.1) 0 1 (0.9)
HPV 45/70 1 (1.1) 0 1 (0.9)
HPV 16/44/52 1 (1.1) 0 1 (0.9)
Total 92 20 114a
a Includes two additional cases of adenosquamous carcinomas.BMC Infectious Diseases 2008, 8:85 http://www.biomedcentral.com/1471-2334/8/85
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presented with HPV type 16, 21 of the cases with type 18,
10 with type 45, four with type 31, two with type 35, three
single infections with types 39, 51, and 52, three double
infections and one triple infection. In the adenocarcino-
mas, 10 were found to have HPV type 18, 7 type 16, one
type 45, and one type 51. Concurrent CIN lesions were
seen in 18 cases with single HPV infections and one case
with multiple HPV types. No differences in HPV detection
were observed between the cases with and without pre-
neoplastic lesions (Table 3).
Discussion
This study shows that HPV/DNA was detected in 114 out
of 186 invasive cervical cancer samples, giving an overall
HPV prevalence of 61.3% of the samples. If the β-globin
gene results are taken into account, then HPV was
detected in 100% of the samples from which cellular DNA
was obtained.
Specific HPV genotypes were identified in 109 cases using
the highly sensitive SPF10 LiPA technology. Most of the
infections were due to single HPV types with only four
cases due to multiple infections. HPV 16 and 18
accounted for more than 70% of the cases, while the
remaining were due to the other HPV types, with HPV 45
constituting a major proportion. In squamous cell carci-
nomas, single infections due to HPV 16 and 18 occurred
in 70% of cases, while in adenocarcinomas these two
types occurred in 85% of cases. Of particular note is the
high proportion of squamous cell carcinomas (10.9%)
due to HPV 45. Almost all infections were high risk HPV
types, with exception of two low risk HPV (44 and 70)
which were seen as part of multiple infections. There were
only 5 samples classified as HPV X (HPV/DNA positive
and genotype negative); we hope to be able to genotype
these samples in the future. HPV 16 and 18 were the 2
most common types identified throughout the study
period indicating viral genotype stability in an era in
which HIV started to emerge.
The prevalence of HPV DNA in cervical cancer varies in
many studies, with some investigators reporting almost
100% [2,4]. This is probably attributable to the efficient
extraction of intact DNA from the fresh cervical scrapes or
cervical tissues used in these studies. The prevalence of
HPV positive samples in our study is relatively low, but
higher than that found in cervical cancer cases from Mau-
ritius [15]. Similar low detection rates of HPV in archival
cervical tissue have been reported recently from Norway
[16].
In our study, all the HPV/DNA negative samples were
tested for β-globin gene. All were found to be β-globin
gene negative, although the β-globin gene primer used
was slightly longer than the very short primer used in the
DEIA reaction. Thus, the low detection rate is very likely
due to poor quality of the DNA in some archival tissue
samples. It has been demonstrated that suboptimal
processing of specimens in the histological process such
as the use of unbuffered formalin as a fixative, which was
common before 1970, may yield DNA that is unsuitable
for HPV detection [16]. In a subset of 200 samples from
the large international RIS HPV TT study, the HPV nega-
tive samples were further explored and 89% of them were
found to be β-globin gene negative, thus attributing this
relatively high rate of HPV negativity to the poor quality
of these retrospective samples. It was also found that ade-
nocarcinomas were more likely to be HPV negative than
squamous cell carcinomas [17].
HPV 16 and 18 are the major aetiological risk factors for
cervical carcinoma. Our overall prevalence of the two
major HPV types (16 and 18) was over 70%, which is sim-
ilar to the IARC multicentric case-control study by Castell-
sague et al. [1], the study by Hammouda et al. from
Algeria [18] that both used fresh samples and GP5+/6+
PCR assay, as well as the most recently meta analysis of
the published literature [9,10]. The study of Castellsague
et al. [1], which provides pooled data of eight case control
studies conducted in North Africa (Algeria, Morocco),
South America (Brazil, Paraguay, Peru) and South East
Asia (India, Thailand, Philippines), showed HPV 16 prev-
alence of cervical adenocarcinomas of 42.7%, HPV 18 at
31.8% and HPV45 3.8% [1]. However, regional differ-
ences were noticeable with a high prevalence of HPV 16 in
North Africa and South America, while in South East Asia
there was a high prevalence of HPV 18. A recent study
from Mozambique [19] on invasive cervical cancer
reported a similar prevalence of HPV 16 (about 47%) and
of HPV 16 and 18 combined (about 71%) as in our study.
Compared with the results of pooled analyses of invasive
cervical cancer from different continents [9,10,20], our
study presents a lower prevalence of HPV 16 (44.7%) than
in Europe, America, Northern Africa and South Asia but
comparable with Sub-Saharan Africa, while the HPV 18
prevalence is higher (28.8%) than in all regions [9]. Con-
sidering the adenocarcinomas only [1], the prevalence of
HPV 16 in our study is lower (35.0%) than in North Africa
(72.7%), South America (71.7%) and comparable with
Table 3: Multiple HPV genotypes in invasive cervical carcinoma 
cases with and without concurrent CIN lesions
HPV + (1 type) HPV + (>1 type) Total
No CIN 87 (96.7%) 3 (3.3%) 90
With CIN 1/2/3 18 (94.7%) 1 (5.3%) 19
Total 105 4 109
p > 0.05BMC Infectious Diseases 2008, 8:85 http://www.biomedcentral.com/1471-2334/8/85
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the prevalence in South-East Asia (34.6%). The prevalence
of HPV 18 in adenocarcinomas in our study (50%) is
somewhat lower than in South East Asia, but more than
twice higher than in the other regions.
The causes of the regional differences in HPV subtype
prevalence need clarification, e.g. the results from Mauri-
tius [15], where only HPV 18 was detected, warrants a fol-
low up study. The proportion of HPV types in the two
major histological types of cervical carcinoma, i.e. squa-
mous cell carcinoma and adenocarcinoma have been
noted to vary, although HPV 16 tend to predominate in
squamous carcinomas and HPV 18 in adenocarcinomas.
In the study of Bosch et al. [4] HPV 16 occurred in 51.2%
and 28% of squamous carcinomas and adenocarcinomas
respectively, while the prevalence of HPV 18 was 56% in
adenocarcinomas and 12.1% in squamous carcinomas. In
distinction from Bosch et al. results [4], our data shows a
lower prevalence of HPV 16 in squamous cell carcinomas
but a higher in adenocarcinomas, and a higher prevalence
of HPV 18 in squamous tumours, lower in adenocarcino-
mas. We also did not observe types 31, 39 and 52 in ade-
nocarcinomas, suggesting that these types may be less
commonly associated with risk of adenocarcinomas
which is in accordance with previously reported data [1].
The absence of these types was also found by other inves-
tigators [18,21] but not by the preliminary data of the RIS
HPV TT study [22].
One of the interesting findings of our study was the five
cases in which the samples were positive for HPV, but spe-
cific HPV genotypes could not be identified. This raises
the possibility that there may be some unidentified HPV
types or that some additional HPV types could have a
wider range of probes. In a study in Mozambique [23],
HPV specific types could not be identified in 19% of the
HPV positive cases, and this failure was attributed to the
limited number of HPV specific probes used.
Multiple infections were seen in only four HPV positive
cases (3.5%) in this study. This is similar to some previous
studies where the prevalence varied from 2.5% in Spain
and Columbia [5], 3.9% in Thailand [6], 4.3% in Brazil
[24], 7.9% in Morocco [25], and 12.9% in women with
squamous tumour in Peru [26]. However, much higher
rates were also reported by other workers, from 19.3% in
Paraguay [27], 32.2% in Korea [28], 32% in Costa Rica
[29] and 34.3% in Mozambique [30]. These differences
could be due to underlying prevalence of multiple infec-
tions in the various populations or to differences in the
methods used in detection and diagnosis [31].
Whether multiple HPV infections are involved in cervical
cancer pathogenesis is rather unclear. Herrero et al. found
that the risk of cervical cancer associated with HPV 16
alone is similar or greater than the risk associated with
multiple infections (HPV 16 plus other HPV) [29]. The
results of Lee et al. found multiple infections associated
with increased cervical cancer risk [32]. Although the
number of cases in our study is rather small, the results
have some important implications. If the HPV vaccines
under trial containing 16 and 18 antigens are close to
100% efficacy [11,13], then one could assume that about
70% of cervical cases would be prevented by the use of the
vaccine. It also raises the question whether other HPV
types should be included in future HPV vaccines. This is of
concern because of multiple infections or infection with
other common HPV genotypes which could account for
5% to 10% of cervical cancer cases. The results of our
study are in agreement with previous reports by Ham-
mouda et al. [18], and Castellsague et al. [1].
Our study had a number of strengths. The method we
used is sensitive and has high efficacy in comparison with
other methods using other general HPV primer sets [14].
In addition, extreme precautions were undertaken to
avoid contamination, and stringent SOP (standard of pro-
cedures) were applied throughout the study. To avoid
false positive results, controls consisting of non-tumour
tissue blank paraffin sections and other negative control
samples were simultaneously tested in each of the differ-
ent steps of analysis.
One limitation of our study was the relatively small
number of cases tested. Since the specimens came from
different parts of the country, the duration of fixation
were not uniform and could have contributed to some
cases being negative for HPV. In addition, the use of non
buffered formalin could also have deteriorated the DNA,
resulting in false negative results.
In our study we did not have information on HIV serol-
ogy. HIV infection is a risk factor for pre cervical cancer
lesions [33,34] and also probably for invasive cervical
cancer [34], although some earlier studies did not find any
associations [35]. Patients with HIV seem to have infec-
tions with a broader spectrum of HPV types other than
HPV 16, and more prone to simultaneous multiple HPV
infections. The prevalence of HIV in Uganda could have
been as high as 20% during part of the time when the
samples were collected. This is based on HIV sero-
prevalance among pregnant women which rose from 10%
in 1985 to around 30% in 1990–1992 [36]. Although this
is a very high rate of HIV, we did not detect in our samples
a different HPV genotype distribution of the most fre-
quent types, neither a higher number of multiple infec-
tions.BMC Infectious Diseases 2008, 8:85 http://www.biomedcentral.com/1471-2334/8/85
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Conclusion
The results of our study show that the HPV type distribu-
tion can be determined using existing archived biological
materials, such as paraffin blocks, allowing evaluating
changes over time, and reaffirm the role of HPV in cervical
cancer pathogenesis in the Ugandan population. HPV 16
and 18 account for about 75% of cases while about 20%
are due to other HPV genotypes, and the remaining due to
multiple HPV types. The results suggest that more HPV
types are yet be identified and recommend that future
HPV vaccines be tailored according to local HPV type dis-
tribution.
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